
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.
Medication Pearl of the Day: Efgartigimod alfa-fcab (Vyvgart)
Indication: Efgartigimod alfa-fcab (Vyvgart)is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive.
Insight:
Sources:






